180 related articles for article (PubMed ID: 18676768)
1. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Mustafa A; Kruger WD
Clin Cancer Res; 2008 Aug; 14(15):4935-42. PubMed ID: 18676768
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Badawi AF; Eldeen MB; Liu Y; Ross EA; Badr MZ
Cancer Res; 2004 Feb; 64(3):1181-9. PubMed ID: 14871855
[TBL] [Abstract][Full Text] [Related]
3. Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.
Ramer R; Walther U; Borchert P; Laufer S; Linnebacher M; Hinz B
J Lipid Res; 2013 Nov; 54(11):3116-29. PubMed ID: 23943857
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro.
Uram Ł; Misiorek M; Pichla M; Filipowicz-Rachwał A; Markowicz J; Wołowiec S; Wałajtys-Rode E
Molecules; 2019 Oct; 24(20):. PubMed ID: 31652556
[TBL] [Abstract][Full Text] [Related]
5. Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents-Comparative Studies on Normal and Immortalized Cell Lines, and on
Uram Ł; Pieńkowska N; Misiorek M; Szymaszek Ż; Twardowska M; Siorek M; Wołowiec S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542198
[TBL] [Abstract][Full Text] [Related]
6. Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines.
Uram Ł; Filipowicz A; Misiorek M; Pieńkowska N; Markowicz J; Wałajtys-Rode E; Wołowiec S
Eur J Pharm Sci; 2018 Nov; 124():1-9. PubMed ID: 30118847
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A₂ and peroxisome proliferator-activated receptor gamma.
Zhang M; Xu ZG; Shi Z; Shao D; Li O; Li W; Li ZJ; Wang KZ; Chen L
Mol Cell Biochem; 2011 Sep; 355(1-2):233-40. PubMed ID: 21559762
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.
Shirode AB; Sylvester PW
Biomed Pharmacother; 2010 May; 64(5):327-32. PubMed ID: 19954924
[TBL] [Abstract][Full Text] [Related]
9. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Lev-Ari S; Zinger H; Kazanov D; Yona D; Ben-Yosef R; Starr A; Figer A; Arber N
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S276-80. PubMed ID: 16507392
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
11. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Brown PH; Subbaramaiah K; Salmon AP; Baker R; Newman RA; Yang P; Zhou XK; Bissonnette RP; Dannenberg AJ; Howe LR
Cancer Prev Res (Phila); 2008 Aug; 1(3):208-14. PubMed ID: 19138958
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
Wang YX; Gao JX; Wang XY; Zhang L; Liu CM
Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
Basu GD; Pathangey LB; Tinder TL; Lagioia M; Gendler SJ; Mukherjee P
Mol Cancer Res; 2004 Nov; 2(11):632-42. PubMed ID: 15561779
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.
Dhawan D; Jeffreys AB; Zheng R; Stewart JC; Knapp DW
Mol Cancer Ther; 2008 Apr; 7(4):897-904. PubMed ID: 18413803
[TBL] [Abstract][Full Text] [Related]
16. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
[TBL] [Abstract][Full Text] [Related]
17. Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model.
Woditschka S; Haag JD; Mau B; Lubet RA; Gould MN
Breast Cancer Res; 2008; 10(1):R18. PubMed ID: 18279516
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.
Adhami VM; Malik A; Zaman N; Sarfaraz S; Siddiqui IA; Syed DN; Afaq F; Pasha FS; Saleem M; Mukhtar H
Clin Cancer Res; 2007 Mar; 13(5):1611-9. PubMed ID: 17332308
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]